What Is IGF-1 LR3? Benefits, Research & Safety

IGF-1 (Insulin-like Growth Factor 1) was first characterised in the 1970s and recognised as a key mediator of growth hormone's biological effects. Understanding of its physiology led to therapeutic development of recombinant human IGF-1 (mecasermin) for certain growth disorders. The development of IGF-1 LR3 arose from efforts to create more potent and longer-lasting analogues for research purposes. Scientists discovered that native IGF-1's biological activity is largely regulated by IGF binding proteins (IGFBPs), which sequester the hormone and limit its free, active concentration. By engineering specific modifications—the N-terminal extension and the arginine substitution—researchers created a variant with dramatically reduced IGFBP binding. This resulted in much higher free IGF-1 activity and a significantly extended half-life. IGF-1 LR3 became a valuable research tool for studying IGF-1 physiology independent of binding protein regulation. It allowed researchers to examine the effects of sustained, high IGF-1 receptor activation. The peptide never progressed to clinical development due to safety concerns related to its potency. However, it became available through research chemical suppliers and gained popularity in bodybuilding communities, leading to concerns about unregulated use.